ACTEMRA MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

Global Actemra Market Size and Forecast – 2025 to 2032

The Global Actemra Market is estimated to be valued at USD 3,023.6 Mn in 2025 and is expected to reach USD 2,373.6 Mn by 2032, declining at a compound annual growth rate (CAGR) of -3.4% from 2025 to 2032.

Key Takeaways of the Global Actemra Market

• Rheumatoid arthritis holds the largest market share by indication, accounting for an expected 52.2% in 2025, due to its high prevalence and the proven effectiveness of Actemra in treating this autoimmune disorder
• In terms of strength, the 80 mg/4 mL (20 mg/mL) formulation is expected to lead the market with a 35.2% share in 2025
• As for packaging, the single-dose vials segment is expected to dominate, contributing 60.2% to the Actemra market in 2025
• North America is expected to lead the market, holding a share of 37.3% in 2025. Asia Pacific is anticipated to be the fastest-growing region, with a market share of 25.5% in 2025.

Market Overview

The market trend for the Actemra market indicates a gradual decline over the forecast period. Factors contributing to this trend may include increased competition from biosimilars, the emergence of alternative therapies, and potential changes in healthcare policies and reimbursement scenarios. However, the market may still benefit from the growing prevalence of rheumatoid arthritis and other autoimmune disorders, as well as the potential expansion of Actemra's indications in the future.

Current Events and Its Impact

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights

To learn more about this report, Request sample copy

Actemra Market Insights, By Indication - Rheumatoid Arthritis (RA) contributes the highest market share due to its high prevalence and the effectiveness of Actemra in managing this autoimmune disorder

In terms of indication, rheumatoid arthritis contributes the highest share of the market with an estimated 52.2% in 2025 owing to its prevalence and the effectiveness of Actemra in treating this autoimmune disorder. Rheumatoid Arthritis (RA) is a chronic inflammatory condition that primarily affects the joints, causing pain, swelling, stiffness, and potential joint damage. The global burden of RA is significant, with millions of people worldwide suffering from this debilitating disease.

Actemra, with its unique mechanism of action targeting the IL-6 receptor, has proven to be a game-changer in the management of RA. Its ability to reduce inflammation, improve physical function, and slow down joint damage has made it a preferred choice among healthcare providers and patients alike. The drug's efficacy in treating RA patients who have had an inadequate response to traditional disease-modifying antirheumatic drugs (DMARDs) or tumor necrosis factor (TNF) inhibitors drug has further solidified its position in the market.

For instance, in June 2023, according to WHO finding, rheumatoid arthritis (RA) is a chronic condition that causes joint pain, stiffness, and swelling, affecting around 18 million people worldwide, mostly women over 55. It often impacts joints in the hands, wrists, and knees. If untreated, RA can lead to serious joint damage and other health problems. While the exact cause is unclear, risk factors include smoking, obesity, and pollution. Early treatment can manage symptoms, and rehabilitation or surgery may be needed for severe cases.

Actemra Market Insights, By Strength - The 80 mg/4 mL strength formulation is the dominant segment, offering convenience, dosing flexibility, and suitability for a wide range of patients

In terms of strength, the 80 mg/4 mL (20 mg/mL) formulation of Actemra contributes the highest share of the market with an estimated 35.2% in 2025. This can be attributed to several factors, including its convenience, dosing flexibility, and suitability for a wide range of patients.

The 80 mg/4 mL strength of Actemra is administered as an intravenous infusion, making it a convenient option for patients who prefer less frequent dosing compared to subcutaneous injections. This formulation allows for weight-based dosing, ensuring that patients receive the optimal amount of medication based on their individual needs. The flexibility in dosing is particularly important for patients with RA, as the disease severity and response to treatment can vary greatly from person to person.

Actemra Market Insights, By Packaging - Single-dose vials dominate the market due to their precision in dosing, flexibility for personalized treatment

In terms of packaging, single-dose vials contribute the highest share of the Actemra market with an estimated share of 60.2% in 2025. This can be attributed to several advantages that single-dose vials offer over other packaging options, such as single-dose prefilled syringes or autoinjectors.

Single-dose vials of Actemra provide a high degree of dosing accuracy and flexibility, which is crucial for personalized treatment. The vials allow healthcare professionals to precisely measure and administer the required dose based on the patient's weight and disease severity. This level of customization is particularly important in the treatment of RA, where individual patient responses can vary significantly.

Pricing Analysis of Actemra

• The pricing of Actemra varied significantly across global markets in 2024, with prices fluctuating based on region and healthcare infrastructure. In high-income countries like the U.S., Finland, and Italy, the price for the 20 mg/mL IV vial ranges between USD 513 and USD 577, reflecting the advanced healthcare systems and higher pharmaceutical pricing norms. In contrast, lower-income countries such as India, Bangladesh, and Colombia see much more affordable prices, with costs as low as USD 141 for the same dosage, indicating disparities in drug access and healthcare affordability.
• This variation in Actemra’s pricing underscores the influence of multiple factors, including local healthcare policies, insurance structures, and market competition. For instance, the U.S. leads with the highest price, likely due to the lack of universal health insurance coverage and the presence of high retail drug costs. Meanwhile, countries like Malaysia and Saudi Arabia offer relatively lower prices, influenced by government subsidies or different pricing agreements with pharmaceutical companies. These pricing differences highlight the ongoing challenges in ensuring equitable access to biologic treatments like Actemra across diverse economic landscapes.

Regional Insights

To learn more about this report, Request sample copy

North America Actemra Market Analysis and Trends

In North America, the Actemra market, while still significant, has been experiencing slow growth, with a negative compound annual growth rate (CAGR), contributing an estimated 37.3% of the global market share in 2025. The region benefits from a well-established healthcare infrastructure and a high adoption rate of advanced therapies. However, market growth has been constrained by factors such as high treatment costs and the increasing availability of alternative therapies. Despite these challenges, the presence of major pharmaceutical companies like Genentech (a subsidiary of Roche) continues to support the market. These companies have invested in research and development, introducing innovative formulations and delivery systems. Additionally, favorable reimbursement policies and government initiatives aimed at supporting the treatment of rheumatoid arthritis and other inflammatory conditions have provided some stability to the market, although overall growth remains subdued due to emerging biosimilars and pricing pressures.

Asia Pacific Actemra Market Analysis and Trends

In the Asia Pacific region, the Actemra market, while still experiencing growth, is seeing a slower pace with a negative compound annual growth rate (CAGR), contributing an estimated 25.5% of the global market share in 2025. This region has traditionally been driven by factors such as the rising prevalence of rheumatoid arthritis and other autoimmune disorders, along with increasing healthcare expenditure and awareness of advanced treatment options. However, the market's growth has been tempered by challenges like high treatment costs and the growing competition from biosimilars.

Countries like China and India have made significant strides in healthcare spending, improving access to biologics such as Actemra, but pricing pressures continue to limit broader adoption. Additionally, the expanding middle class and aging population have contributed to sustained demand for effective therapies, yet the market growth remains slow. Local pharmaceutical companies, like Chugai Pharmaceutical (a subsidiary of Roche) in Japan, have helped maintain some market momentum through their strong manufacturing and distribution networks, though overall growth remains sluggish.

Global Actemra Market Outlook for Key Countries

U.S. Actemra Market Trends

The U.S. market for Actemra, while still substantial, is experiencing slow growth with a negative compound annual growth rate (CAGR). The high prevalence of rheumatoid arthritis and a robust healthcare system have traditionally driven the market. However, challenges such as high treatment costs, the emergence of biosimilars, and increasing competition from alternative therapies have hindered further expansion. Key players like Genentech continue to promote the drug's benefits and expand its indications, but the favorable reimbursement landscape and strong patient advocacy groups are no longer enough to offset the slower market growth.

According to the data provided by Centers of Disease Control and Prevention (CDC) in 2022, the age-adjusted prevalence of diagnosed arthritis in adults aged 18 and older in the U.S. was 18.9%. Women (21.5%) were more likely to have arthritis than men (16.1%). The prevalence increased with age, from 3.6% in adults aged 18-34 to 53.9% in those 75 and older.

Japan Actemra Market Trends

Japan remains a significant market for Actemra, but its growth is also slowing down. The country’s high prevalence of rheumatoid arthritis has supported the drug's adoption, but the market is facing similar challenges. Despite Chugai Pharmaceutical's strong presence and its ongoing collaboration with healthcare providers to increase the drug’s adoption, the overall market for Actemra is experiencing gradual stagnation, driven by pricing pressures and the growing availability of biosimilars.

For instance, on June 16, 2025, a study published in Annals of the Rheumatic Diseases Journal which shows a 13.2% rise in global rheumatoid arthritis (RA) cases from 1990 to 2021, now affecting 17.9 million people, with younger populations increasingly impacted. Countries with higher sociodemographic indices, like Japan, have seen a 22% decrease in RA burden, due to early diagnosis, biologic therapies, and anti-inflammatory diets.

U.K. Actemra Market Trends

In the U.K., the Actemra market is experiencing slower growth due to the increasing adoption of biosimilars and oral therapies like JAK inhibitors, which offer more convenient treatment options. The focus is shifting towards personalized medicine and combination therapies, which may optimize treatment outcomes for patients with autoimmune diseases like rheumatoid arthritis. Although Actemra remains a key biologic therapy, these trends suggest a more competitive and diversified treatment landscape moving forward.

For instance, a 2023 study published in The Lancet analyzed health records of over 22 million individuals in the U.K. to assess the incidence and prevalence of autoimmune diseases from 2000 to 2019. The study found that 10.2% of the population was affected by autoimmune diseases, with women being more impacted than men. Over the period, the incidence of autoimmune diseases increased, with Celiac disease, Sjogren’s syndrome, and Graves’ disease showing the largest rises.

China Actemra Market Trends

In China, the market for Actemra is growing at a slower rate than expected, despite the increasing prevalence of rheumatoid arthritis and other inflammatory conditions. While the country’s expanding healthcare infrastructure and government initiatives to improve access to advanced therapies have been key drivers, the rise of biosimilars and pricing challenges have tempered the growth. Local pharmaceutical companies, such as Shanghai Roche Pharmaceuticals, continue to play a significant role in manufacturing and distributing Actemra, but their efforts are not enough to counter the overall decline in market growth.

Reimbursement Programs for Actemra

• The Genentech Co-pay Program helps eligible patients with commercial insurance pay as little as USD 5 per ACTEMRA treatment, with assistance up to USD 15,000 per year. It is available for U.S. FDA-approved uses of ACTEMRA for patients aged 18 or older, who do not use state or federal healthcare programs (e.g., Medicare, Medicaid). If a patient is eligible, the co-pay assistance can reduce their out-of-pocket costs, though patients are responsible for any remaining expenses after the annual limit. The program is not available to patients whose prescription is covered by government insurance programs or if the patient has other assistance for the same expenses.
• For those without insurance or with financial concerns, the Genentech Patient Foundation provides free ACTEMRA to eligible patients, based on income criteria (under USD 150,000 for uninsured patients and those whose plans do not cover ACTEMRA). The enrollment requires both the Patient Consent Form and a Prescriber Foundation Form.

Market Players, Key Developments, and Competitive Intelligence

To learn more about this report, Request sample copy

Key Developments

• In September 2023, Chugai Pharmaceutical Co., Ltd. announced that the Ministry of Health, Labour and Welfare in Japan has approved an additional indication for Actemra (tocilizumab) to treat cytokine release syndrome (CRS) induced by cancer therapy. Actemra was previously approved for CRS caused by tumor-specific T-cell infusion therapy in March 2019. With this new approval, Actemra can now be used as an anti-cytokine therapy for CRS associated with various cancer treatments.
• In December 2022, Roche announced that the U.S. FDA approved Actemra (tocilizumab) intravenous (IV) for the treatment of COVID-19 in hospitalized adults who are receiving systemic corticosteroids and need supplemental oxygen, non-invasive or invasive mechanical ventilation, or ECMO. Actemra is the first U.S. FDA-approved monoclonal antibody for treating COVID-19 and is recommended as a single 60-minute IV infusion.
• In March 2021, Genentech, a member of the Roche Group, announced that the U.S. FDA approved Actemra (tocilizumab) subcutaneous injection for slowing the decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD). This approval makes Actemra the first biologic therapy approved for this rare, debilitating condition. SSc-ILD affects up to 75,000 people in the U.S., with approximately 80% of SSc patients developing interstitial lung disease.

Market Report Scope

Actemra Market Report Coverage

Actemra Market Dynamics

To learn more about this report, Request sample copy

Actemra Market Driver - Increasing Prevalence of Autoimmune Diseases

The global Actemra market is experiencing significant growth due to the rising prevalence of autoimmune diseases worldwide. Autoimmune disorders occur when the body's immune system mistakenly attacks healthy cells, leading to chronic inflammation and tissue damage. Actemra, a medication developed by Roche, targets the interleukin-6 (IL-6) receptor, which plays a crucial role in the inflammatory process associated with various autoimmune conditions such as rheumatoid arthritis, giant cell arteritis, and systemic juvenile idiopathic arthritis. As the incidence of these diseases continues to rise, the demand for effective treatments like Actemra is expected to increase correspondingly. Moreover, the growing awareness among patients and healthcare professionals about the benefits of targeted therapies in managing autoimmune disorders is further driving the adoption of Actemra in clinical practice.

For instance, in 2024, according to research at the National Institute of Environmental Health Sciences (NIEHS), autoimmune diseases are on the rise, particularly among women. Studies indicate that these conditions affect at least 1 in 20 adults in the U.S., leading to significant personal and societal impacts. In the U.K., research shows that 1 in 10 people are affected by autoimmune diseases.

Actemra Market Opportunity - Expanding Research and Development Activities

The global Actemra market presents a significant opportunity through the expansion of research and development activities. As the understanding of the underlying mechanisms of various inflammatory and autoimmune disorders advances, there is immense potential for exploring new indications and applications for Actemra. Ongoing research efforts aim to uncover the therapeutic benefits of Actemra in treating a wider range of conditions beyond its current approved indications. By investing in research and development, market players can identify novel disease areas where Actemra's mechanism of action could prove beneficial, thus expanding its market reach. Additionally, research activities focused on optimizing the drug's formulation, delivery methods, and dosing regimens can enhance its efficacy, safety, and patient convenience. Collaborative research initiatives between pharmaceutical companies, academic institutions, and clinical research organizations can accelerate the discovery and development process, leading to innovative breakthroughs.

Analyst Opinion (Expert Opinion)

• The global Actemra market is experiencing a steady decline, primarily driven by the increasing availability of biosimilars and the growing preference for more cost-effective treatment options. While Actemra, a leading monoclonal antibody used for conditions like rheumatoid arthritis and cytokine release syndrome, has seen widespread adoption in the past, its market share is now under pressure from generic alternatives and regulatory shifts favoring lower-cost drugs. Despite its proven efficacy, the high cost of Actemra and its limited growth prospects in newer indications are contributing to its gradual market contraction. Additionally, the impact of the COVID-19 pandemic has further stressed healthcare budgets, reducing the willingness of health systems to adopt expensive treatments.
• Recent conferences, such as the American College of Rheumatology's annual meetings and the European League Against Rheumatism (EULAR) congress, have provided a platform for discussing new therapies and treatment paradigms in autoimmune diseases and cytokine release syndrome. These events have been crucial for fostering collaborations, presenting emerging research, and discussing the market’s evolving landscape. Governments and healthcare providers are also pushing for initiatives aimed at improving patient access to biologic therapies, including Actemra, through cost-reduction strategies, such as biosimilar approval pathways. However, with competition intensifying and pricing pressures mounting, the Actemra market outlook appears to be on a steady decline rather than a growth trajectory.

Market Segmentation

•  Indication Insights (Revenue, USD Mn, 2020 - 2032)
  • Rheumatoid Arthritis
  • Giant Cell Arteritis (GCA)
  • Polyarticular Juvenile Idiopathic Arthritis (PJIA)
  • Systemic Juvenile Idiopathic Arthritis (SJIA)
  • Cytokine Release Syndrome (CRS)
  • Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD)
•  Strength Insights (Revenue, USD Mn, 2020 - 2032)
  • 80 mg/4 mL (20 mg/mL)
  • 200 mg/10 mL (20 mg/mL)
  • 400 mg/20 mL (20 mg/mL)
  • 162 mg/0.9 mL for Injection
•  Packaging Insights (Revenue, USD Mn, 2020 - 2032)
  • Single-dose vials
  • Single-dose prefilled syringe or autoinjector
•  Route of Administration Insights (Revenue, USD Mn, 2020 - 2032)
  • Subcutaneous
  • Intravenous
•  Age Group Insights (Revenue, USD Mn, 2020 - 2032)
  • Adult
  • Pediatric
  • Geriatric
•  Sales Channel Insights (Revenue, USD Mn, 2020 - 2032)
  • Online
  • Offline
•  End User Insights (Revenue, USD Mn, 2020 - 2032)
  • Hospitals
  • Specialized Infusion Centers
  • Others (Academics and Research Institutes, etc.)
• Regional Insights (Revenue, USD Mn, 2020 - 2032)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
  • Genentech (Part of Roche)
  • Chugai Pharmaceutical Co., Ltd.

Sources

Primary Research Interviews

• Interviews with healthcare providers (e.g., rheumatologists, immunologists)
• Interviews with key opinion leaders (KOLs) in the field of autoimmune diseases
• Interviews with pharmacists and medical professionals involved in biologics
• Interviews with patients using Actemra and other biologic therapies

Databases

• National Health Service (NHS) UK
• U.S. National Institutes of Health (NIH)
• Centers for Disease Control and Prevention (CDC)
• World Health Organization (WHO)
• European Medicines Agency (EMA)
• National Institute for Health and Care Excellence (NICE)

Magazines

• Pharmaceutical Technology
• BioPharma Reporter
• The Pharmaceutical Journal
• Rheumatology News
• The Lancet Rheumatology
• Journal of Clinical Rheumatology

Journals

• Annals of Rheumatic Diseases
• The Lancet Rheumatology
• Rheumatology Advances in Practice
• Journal of Rheumatology

 Newspapers

• The Guardian (UK)
• The New York Times
• The Financial Times
• The Washington Post
• The Times (UK)
• The Wall Street Journal

Associations

• The American College of Rheumatology (ACR)
• British Society for Rheumatology (BSR)
• European League Against Rheumatism (EULAR)
• Arthritis Foundation
• Global Alliance of Rheumatology Organisations (GARO)

Public Domain Sources

• U.S. National Library of Medicine
• UK National Health Service (NHS) Resources
• National Health Interview Survey (NHIS)
• Centers for Disease Control and Prevention (CDC) Data
• National Institute for Health and Care Excellence (NICE) Guidelines

Proprietary Elements

• CMI Data Analytics Tool: Proprietary analytics tool to analyze real-time market trends, consumer behavior, and technology adoption in market
• Proprietary CMI Existing Repository of Information for Last 8 Years